Standard BioTools (NASDAQ:LAB – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.05, FiscalAI reports. The business had revenue of $19.39 million during the quarter, compared to analyst estimates of $18.80 million. Standard BioTools had a net margin of 100.36% and a negative return on equity of 7.57%.
Standard BioTools Trading Down 0.3%
NASDAQ LAB traded down $0.00 on Wednesday, hitting $0.61. 421,840 shares of the company traded hands, compared to its average volume of 2,285,092. The company has a market capitalization of $240.38 million, a price-to-earnings ratio of 2.78 and a beta of 1.52. The business’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.91. Standard BioTools has a 52-week low of $0.59 and a 52-week high of $1.72.
Analysts Set New Price Targets
Separately, Weiss Ratings cut Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $1.35.
Read Our Latest Research Report on Standard BioTools
Standard BioTools Company Profile
Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.
The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.
Further Reading
- Five stocks we like better than Standard BioTools
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
- Bloom Energy: The Off-Grid Answer to AI’s Power Drain
- Space Race 2.0: Intuitive Machines Secures Another NASA Contract
- Zebra Technologies’ Sell-Off: 3 Factors Investors May Be Missing
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
